Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082707 | 0.86 | TDP1 (0.56) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL25014915 | 0.79 | TDP1 (0.50) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL10037268 | 0.79 | TDP1 (0.50) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL15083132 | 0.79 | TDP1 (0.50) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL1042383 | 0.79 | TDP1 (0.59) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL14646688 | 0.79 | TDP1 (0.50) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL12103908 | 0.78 | TDP1 (0.49) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL1584489 | 0.78 | TDP1 (0.49) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL14755649 | 0.78 | TDP1 (0.49) | TDP1MEN1KMT2AGAAIDO1 | |
| SCHEMBL903325 | 0.78 | TDP1 (0.49) | TDP1MEN1KMT2AGAAIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2025-01-02 | — | — | US | disclosed |
| US-20240417418-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2024-12-19 | — | — | US | disclosed |
| EP-4401788-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402149-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4402150-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| EP-4286394-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-4286004-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023067126-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067124-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | BioNTech SE (DE) | 2023-04-27 | — | — | WO | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013116200-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2011146638-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | CERULEAN PHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TDP1 1801/4885MEN1 1397/4885KMT2A 3696/4885 |
| US-20250057960-A1 | OLIGOSACCHARIDE COMPLEXES AND USES | CD4, FUT6, UGCG | TDP1 4398/4885MEN1 3067/4885KMT2A 4793/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TDP1 1095/4885MEN1 2879/4885KMT2A 4529/4885 |
| US-20250002522-A1 | OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | OSTC, FUT6, MAN2B2 | TDP1 1306/4885MEN1 2389/4885KMT2A 4165/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TDP1 1801/4885MEN1 1397/4885KMT2A 3696/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | TDP1 1801/4885MEN1 1397/4885KMT2A 3696/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TDP1 1095/4885MEN1 2879/4885KMT2A 4529/4885 |
| US-20240417418-A1 | DISULFIDE OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES | DNAJC10, SNRPA, SNRPA1 | TDP1 2292/4885MEN1 3682/4885KMT2A 4190/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TDP1 1095/4885MEN1 2879/4885KMT2A 4529/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | TDP1 1095/4885MEN1 2879/4885KMT2A 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.